Incorporating external data into the analysis of clinical trials via Bayesian additive regression trees

被引:7
|
作者
Zhou, Tianjian [1 ]
Ji, Yuan [2 ]
机构
[1] Colorado State Univ, Dept Stat, 851 Oval Dr, Ft Collins, CO 80523 USA
[2] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
基金
美国国家科学基金会;
关键词
Bayesian method; borrow information; historical control; real-world data; treatment effect; HISTORICAL CONTROL DATA; EARLY TUMOR SHRINKAGE; POWER PRIOR; PRIORS; INFORMATION; COMBINATION; SURVIVAL;
D O I
10.1002/sim.9191
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most clinical trials involve the comparison of a new treatment to a control arm (eg, the standard of care) and the estimation of a treatment effect. External data, including historical clinical trial data and real-world observational data, are commonly available for the control arm. With proper statistical adjustments, borrowing information from external data can potentially reduce the mean squared errors of treatment effect estimates and increase the power of detecting a meaningful treatment effect. In this article, we propose to use Bayesian additive regression trees (BART) for incorporating external data into the analysis of clinical trials, with a specific goal of estimating the conditional or population average treatment effect. BART naturally adjusts for patient-level covariates and captures potentially heterogeneous treatment effects across different data sources, achieving flexible borrowing. Simulation studies demonstrate that BART maintains desirable and robust performance across a variety of scenarios and compares favorably to alternatives. We illustrate the proposed method with an acupuncture trial and a colorectal cancer trial.
引用
收藏
页码:6421 / 6442
页数:22
相关论文
共 50 条
  • [41] Challenges and potential strategies utilizing external data for efficacy evaluation in small-sized clinical trials
    Jiao, Feiran
    Chen, Yeh-Fong
    Min, Min
    Jimenez, Sara
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2022, 32 (01) : 21 - 33
  • [42] Regression analysis of clustered failure time data with informative cluster size under the additive transformation models
    Chen, Ling
    Feng, Yanqin
    Sun, Jianguo
    LIFETIME DATA ANALYSIS, 2017, 23 (04) : 651 - 670
  • [43] Bayesian Design of Superiority Clinical Trials for Recurrent Events Data with Applications to Bleeding and Transfusion Events in Myelodyplastic Syndrome
    Chen, Ming-Hui
    Ibrahim, Joseph G.
    Zeng, Donglin
    Hu, Kuolung
    Jia, Catherine
    BIOMETRICS, 2014, 70 (04) : 1003 - 1013
  • [44] BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS
    Lin, Ruitao
    Shi, Haolun
    Yin, Guosheng
    Thali, Peter F.
    Yuan, Ying
    Flowers, Christopher R.
    ANNALS OF APPLIED STATISTICS, 2022, 16 (04) : 2481 - 2504
  • [45] Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma
    Ishak, K. Jack
    Caro, J. Jaime
    Drayson, Mark T.
    Dimopoulos, Meletios
    Weber, Donna
    Augustson, Bradley
    Child, J. Anthony
    Knight, Robert
    Iqbal, Gulnaz
    Dunn, Janet
    Shearer, Arran
    Morgan, Gareth
    VALUE IN HEALTH, 2011, 14 (05) : 672 - 678
  • [46] External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    Martinez-Torron, Alba
    Alsina, Maria
    Custodio, Ana
    Serra, Olbia
    Cacho Lavin, Diego
    Limon, Maria Luisa
    Sauri, Tamara
    Lopez, Flora
    Visa, Laura
    Granja, Monica
    Martinez Lago, Nieves
    Arrazubi, Virginia
    Vidal Tocino, Rosario
    Hernandez, Raquel
    Aguado, Gema
    Cano, Juana Maria
    Martin Carnicero, Alfonso
    Mangas, Monserrat
    Pimentel, Paola
    Fernandez Montes, Ana
    Macias Declara, Ismael
    Longo, Federico
    Ramchandani, Avinash
    Martin Richard, Marta
    Hurtado, Alicia
    Azkarate, Aitor
    Hernandez Perez, Carolina
    Serrano, Raquel
    Gallego, Javier
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [47] Integrating expert opinions with clinical trial data to analyse low-powered subgroup analyses: a Bayesian analysis of the VeRDiCT trial
    Thirard, Russell
    Ascione, Raimondo
    Blazeby, Jane M.
    Rogers, Chris A.
    BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [48] Bayesian Divide-and-Conquer Propensity Score Based Approaches for Leveraging Real World Data in Single Arm Clinical Trials
    Baron, Eric
    Zhu, Jian
    Tang, Rui
    Chen, Ming-Hui
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2022, 32 (01) : 75 - 89
  • [49] Regenerative surgical treatment of furcation defects: A systematic review and Bayesian network meta-analysis of randomized clinical trials
    Jepsen, Soren
    Gennai, Stefano
    Hirschfeld, Josefine
    Kalemaj, Zamira
    Buti, Jacopo
    Graziani, Filippo
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2020, 47 : 352 - 374
  • [50] Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson's disease
    Chaudhuri, Shomesh E. E.
    Ben Chaouch, Zied
    Hauber, Brett
    Mange, Brennan
    Zhou, Mo
    Christopher, Stephanie
    Bardot, Dawn
    Sheehan, Margaret
    Donnelly, Anne
    McLaughlin, Lauren
    Caldwell, Brittany
    Benz, Heather L. L.
    Ho, Martin
    Saha, Anindita
    Gwinn, Katrina
    Sheldon, Murray
    Lo, Andrew W. W.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023,